ST2 for the Management of Heart Failure - STADE-HF (NCT02963272) | Clinical Trial Compass
CompletedNot Applicable
ST2 for the Management of Heart Failure - STADE-HF
France123 participantsStarted 2017-01-19
Plain-language summary
Heart failure (HF) is a severe disease, burdened with a poor prognosis (30% mortality at 2 years, 30% of rehospitalization within 1 month). It is also a major cause of health burden representing between 1.5 and 2 billions euros per year in France. Approximately 75% of these costs are due to hospitalization.
Besides physical examination and echocardiography, biology may help refine the diagnosis, but also could provide powerful prognostic parameters.
This study aims to assess the value of ST2 in the management of patients admitted for HF to reduce readmission at one month.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Heart failure hospitalization
Exclusion Criteria:
* Other study
* Pregnancy, feeding
* Refusal
* Not possible to perform information
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial tracked rehospitalization as its main outcome — since it's now completed, has any data been published showing whether monitoring the ST2 biomarker actually helped reduce hospital readmissions for heart failure patients like me?
2ST2 is a blood biomarker I may not have heard of before — can you explain how it differs from the markers you're already using to manage my heart failure, and whether tracking it would change anything about my treatment plan?
3Since this study included both diastolic and systolic heart failure, does the type of heart failure I have affect how relevant its findings might be to my situation?
4This trial is listed as 'Phase NA,' which suggests it may have been more of an observational or diagnostic study rather than a test of a new drug — can you help me understand what kind of evidence it would have generated and how much weight to give its results?
5Are there other ongoing or completed studies on ST2 monitoring that you think are more directly relevant to my current stage of heart failure, or is the standard of care already incorporating what this trial was trying to learn?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.